<DOC>
	<DOCNO>NCT02256150</DOCNO>
	<brief_summary>To demonstrate treatment effect lupus nephritis MZR non-inferior standard therapy CTX analyze overall remission rate treatment .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Mizoribine Treatment Lupus Nephritis</brief_title>
	<detailed_description />
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Bredinin</mesh_term>
	<criteria>Patient diagnose SLE accord American College Rheumatology ( ACR ) criterion 1997 ; Patient kidney biopsy within 365 day prior screen confirm class III , III+V , IV , IV+V , V accord pathologic classification International Society Nephrology/Renal Pathology Society ( ISN/RPS ) 2003 ; Patient 24hrurine protein ≥ 1.0g ; SLEDAI &gt; 8 ; Male female patient 18 70 year ( inclusive ) inform consent obtain date ; Patient body weight 40kg 80kg ( inclusive ) screening ; Patients sign inform consent form ; Patient history allergy investigational product ( MZR , CTX ) hormone ; Patient receive accumulated dosage CTX &gt; 3g within one year prior screen . Patient receive immunosuppressant Chinese traditional medicine immunosuppressive effect within 30 day prior screen ; Patient receive prednisone &gt; 1.0mg/kg/day equivalent dose oral glucocorticoid therapy within 30 day prior screen ; Patient receive investigational drug within 30 day prior screen ; Patient receive plasma exchange therapy immunoadsorption therapy within 30 day prior screen ; Patient require pentostatin live vaccine ( include flu vaccine ) ; Patient undergo renal replacement therapy ; Patient receive kidney transplantation ; Patient malignancy ; Patient severe hypertension ( SBP &gt; 160mmHg DBP &gt; 100mmHg ) effectively control ; Patient white blood cell count &lt; 3×109/L /L ( =3.0 GI/L ) ; Patient SCr &gt; 176.8μmol/L ; Patient value &gt; 3 time upper limit normal range AST ALT ; Patient hepatitis B , hepatitis C HIV infection ; Patient serious infection ; Patient unsuitable participate study opinion investigator ( e.g . uncontrolled diabetes , central nervous system lupus , lupus encephalopathy , active psychosis , osteonecrosis femoral head , fulminant hepatitis , peptic ulcer , etc . ) ; Female patient pregnant , currently breast feed willing become pregnant ; Patient disease would affect evaluation efficacy safety .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>